Sutro Biopharma (STRO) 2024 Wells Fargo Healthcare Conference summary

Company overview and platform strategy

• Focused on late-stage clinical development in oncology, leveraging a proprietary platform for antibody-drug conjugates (ADCs) with a goal to deliver higher efficacy and lower toxicity.

• Lead program, Luvelta (luveltamab tazevibulin), targets folate receptor alpha and is in pivotal trials for ovarian cancer, pediatric AML, and non-small cell lung cancer.

• Platform enables next-generation ADCs, including immunostimulatory ADCs (iADCs) that combine cytotoxic and immune-activating payloads in a single homogeneous molecule.

• Technology has also enabled external successes, such as Vaxcyte’s 31-valent pneumococcal conjugate vaccine.

Clinical development and upcoming milestones

• Luvelta is in pivotal trials for ovarian cancer, with a two-part design to meet FDA Project Optimist requirements and enable both accelerated and full approval.

• Ongoing expansion cohort for Luvelta plus bevacizumab; updated data to be presented at ESMO, with further data expected next year.

• Pediatric AML trial is ongoing, aiming to provide a new option for a rare, high-mortality leukemia and potentially secure a Priority Review Voucher.

• Non-small cell lung cancer trial initiated, with early data anticipated next year; focus on patients with ≥25% folate receptor alpha expression.

• Additional pipeline candidates (STRO-004, -005, -006, -007) are advancing, with a research forum planned to discuss platform innovation and new molecules.

Competitive positioning and differentiation

• Luvelta aims to serve a broader patient population, including low and medium folate receptor alpha expressors, potentially doubling the addressable market compared to current therapies.

• All-comer strategy could disrupt the need for biomarker testing and expand access to therapy.

• Early data show consistent efficacy in lower expressor groups, supporting pursuit of a broader label.

• Competitive advantage in Europe due to lack of Elahere availability, facilitating trial recruitment and broader patient mix.

• Success in low/medium expressors would raise the standard of care, making it harder for future competitors to enter.